BSX - Boston Scientific Corporation So'nggi... | Finranks

11.08.2026

Artisan Global Equity Fund Q2 2026 Portfolio Review

The portfolio underperformed the MSCI All Country World Index during Q2. Our stock selection in the financials sector helped the portfolio outperform its benchmark in the sector. Regionally, holdings in Indo-Pacific emerging markets fared best across two themes: electrification and aerospace and defense.

11.08.2026

Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone

Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S.

10.08.2026

Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?

The 2,100 shares were acquired for ~$100,000 on August 5, 2026. This transaction represents a 14% increase in total direct equity holdings.

10.08.2026

Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Michael F. Mahoney deployed ~$10.0 million on August 3, 2026, to acquire ~200,000 shares at a weighted average price of $48.34. The acquisition increased the CEO's total equity holdings by 13%, primarily expanding his direct position in the company.

10.08.2026

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026.

06.08.2026

Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

05.08.2026

Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
BSX	Argus	Hold	undefined >> undefined	July 31st 2026

Boston Scientific Corporation (BSX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Boston Scientific Corporation (BSX)

Artisan Global Equity Fund Q2 2026 Portfolio Review

Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone

Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?

Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test

Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?

Videolar

No Data

Reytinglar oshishi / pasayishi

Search stocks

Boston Scientific Corporation (BSX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Boston Scientific Corporation (BSX)

Artisan Global Equity Fund Q2 2026 Portfolio Review

Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone

Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?

Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test

Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?

Videolar

No Data

Reytinglar oshishi / pasayishi